FDA EIR - Natures Health Options, LLC - September 28, 2021

The FDA conducted a surveillance inspection of Natures Health Options, LLC, a dietary supplement own-label distributor located in Boca Raton, FL, from September 14 to September 28, 2021. The inspection primarily assessed compliance with the regulatory framework for dietary supplements, 21 CFR Part 111, which outlines Good Manufacturing Practices.

The inspection identified significant deficiencies, leading to the issuance of an FDA Form 483, Inspectional Observations, to the company's President/Owner. Key violations included the repeated failure to establish written specifications for the identity, purity, strength, and composition of finished dietary supplements received from contract manufacturers. The company also lacked written specifications for the packaging and labeling of these finished products. A third critical repeat observation was the absence of written procedures for quality control operations, particularly for material review and disposition decisions. These issues highlighted a continuous lack of formal processes to ensure product quality and regulatory adherence.

During the inspection's closeout meeting, the FDA also verbally reminded the firm about potential unauthorized disease claims on its website, specifically regarding a book linking their product to diabetes treatment, an issue previously noted in prior inspections.

Natures Health Options, LLC's management committed to correcting the identified deficiencies and submitting a written response to the FDA within 15 business days. The FDA underscored the serious implications of these findings and the potential for legal sanctions if effective corrective actions are not implemented.